Order Article Reprints

Lombardi A, Viero G, Villa S, Biscarini S, Palomba E, Azzarà C, Iannotti N, Mariani B, Genovese C, Tomasello M, et al. Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients. Biomedicines. 2023; 11(6):1540. https://doi.org/10.3390/biomedicines11061540

Lombardi, Andrea, Giulia Viero, Simone Villa, Simona Biscarini, Emanuele Palomba, Cecilia Azzarà, Nathalie Iannotti, Bianca Mariani, Camilla Genovese, Mara Tomasello, and et al. 2023. "Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients" Biomedicines 11, no. 6: 1540. https://doi.org/10.3390/biomedicines11061540

Lombardi, A., Viero, G., Villa, S., Biscarini, S., Palomba, E., Azzarà, C., Iannotti, N., Mariani, B., Genovese, C., Tomasello, M., Tonizzo, A., Fava, M., Valzano, A. G., Morlacchi, L. C., Donato, M. F., Castellano, G., Cassin, R., Carrabba, M., Muscatello, A., ... Bandera, A. (2023). Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients. Biomedicines, 11(6), 1540. https://doi.org/10.3390/biomedicines11061540